UY34916A - "SOLID PREPARATION CONTAINING ACID [(3S) -6 -) {2´, 6´-DIMETIL-4´- [3- (METILSULFONIL) PROPOXI] BIFENIL-3-IL} METOXI) -2,3-DIHYDRO-1 -BENZOFURAN-3-IL] ACETIC " - Google Patents

"SOLID PREPARATION CONTAINING ACID [(3S) -6 -) {2´, 6´-DIMETIL-4´- [3- (METILSULFONIL) PROPOXI] BIFENIL-3-IL} METOXI) -2,3-DIHYDRO-1 -BENZOFURAN-3-IL] ACETIC "

Info

Publication number
UY34916A
UY34916A UY0001034916A UY34916A UY34916A UY 34916 A UY34916 A UY 34916A UY 0001034916 A UY0001034916 A UY 0001034916A UY 34916 A UY34916 A UY 34916A UY 34916 A UY34916 A UY 34916A
Authority
UY
Uruguay
Prior art keywords
solid preparation
metilsulfonil
bifenil
propoxi
dimetil
Prior art date
Application number
UY0001034916A
Other languages
Spanish (es)
Inventor
Hoshina Wataru
Mima Yasushi
Hohokabe Miyuki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY34916A publication Critical patent/UY34916A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una preparación sólida superior en la propiedad de desintegración y estabilidad de preservación. La presente invención se refiere a una preparación sólida que contiene (1) el compuesto (A) o una de sus sales, (2) metformina o una de sus sales y (3) crospovidona. También se refiere a un compuesto (A) o una de sus sales superiores en la propiedad de disolución.The present invention provides a superior solid preparation in the property of decay and preservation stability. The present invention relates to a solid preparation containing (1) the compound (A) or a salt thereof, (2) metformin or a salt thereof and (3) crospovidone. It also refers to a compound (A) or one of its higher salts in the dissolution property.

UY0001034916A 2012-07-19 2013-07-17 "SOLID PREPARATION CONTAINING ACID [(3S) -6 -) {2´, 6´-DIMETIL-4´- [3- (METILSULFONIL) PROPOXI] BIFENIL-3-IL} METOXI) -2,3-DIHYDRO-1 -BENZOFURAN-3-IL] ACETIC " UY34916A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012161025A JP2015127299A (en) 2012-07-19 2012-07-19 Solid preparation

Publications (1)

Publication Number Publication Date
UY34916A true UY34916A (en) 2014-02-28

Family

ID=48980240

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034916A UY34916A (en) 2012-07-19 2013-07-17 "SOLID PREPARATION CONTAINING ACID [(3S) -6 -) {2´, 6´-DIMETIL-4´- [3- (METILSULFONIL) PROPOXI] BIFENIL-3-IL} METOXI) -2,3-DIHYDRO-1 -BENZOFURAN-3-IL] ACETIC "

Country Status (5)

Country Link
JP (1) JP2015127299A (en)
AR (1) AR092351A1 (en)
TW (1) TW201408290A (en)
UY (1) UY34916A (en)
WO (1) WO2014014129A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102445054B1 (en) 2018-02-13 2022-09-22 길리애드 사이언시즈, 인코포레이티드 PD-1/PD-L1 inhibitors
JP7242702B2 (en) 2018-04-19 2023-03-20 ギリアード サイエンシーズ， インコーポレイテッド PD-1/PD-L1 inhibitor
BR112020026746A2 (en) 2018-07-13 2021-03-30 Gilead Sciences, Inc. COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS TO INHIBIT PD-1, PD-L1 AND / OR THE INTERACTION OF PD-1 / PD-L1 AND TO TREAT CANCER, AND, KIT TO TREAT OR PREVENT CANCER OR A DISEASE OR CONDITION.
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
JP2021104941A (en) * 2019-12-26 2021-07-26 ニプロ株式会社 Tablets with high drug content and manufacturing methods thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
AR035016A1 (en) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd COMPOSITION OF AZOL PROMOTER OF PRODUCTION / SECRETION OF NEUROTROFINE, COMPOSITE PRODROGA OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THE SAME TO PREPARE THIS LAST.
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
PE20040609A1 (en) 2002-11-01 2004-10-29 Takeda Pharmaceutical AROMATIC HETEROCYCLIC COMPOUNDS AS PROMOTERS OF A NEUROTROPHIC FACTOR
EP1564213A4 (en) 2002-11-22 2009-05-27 Takeda Pharmaceutical Imidazole derivative, process for producing the same, and use
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
JP4769082B2 (en) 2003-12-17 2011-09-07 武田薬品工業株式会社 Urea derivatives, their production and use
TWI396686B (en) 2004-05-21 2013-05-21 Takeda Pharmaceutical Cyclic amide derivative, and its production and use
EP1873144B1 (en) 2005-04-20 2014-07-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
PE20070338A1 (en) 2005-08-10 2007-04-16 Takeda Pharmaceutical HETEROCYCLIC DERIVATIVES AS THERAPEUTIC AGENTS FOR DIABETES
JP2007063225A (en) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd Imidazopyridine compound
DK2248812T5 (en) 2006-06-27 2015-01-26 Takeda Pharmaceutical Condensed cyclic compounds as GPR40 receptor modulators
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
MY158052A (en) 2006-10-19 2016-08-30 Takeda Pharmaceutical Indole compound
JPWO2008093639A1 (en) 2007-01-29 2010-05-20 武田薬品工業株式会社 Pyrazole compounds
TW200838515A (en) 2007-02-09 2008-10-01 Takeda Pharmaceutical Fused ring compound
WO2008136428A1 (en) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
JP2011502958A (en) 2007-06-19 2011-01-27 武田薬品工業株式会社 Glucokinase activated indazole compound
JP2012161025A (en) 2011-02-02 2012-08-23 Mitsubishi Electric Corp Cable diagnostic device and cable diagnostic method

Also Published As

Publication number Publication date
WO2014014129A1 (en) 2014-01-23
JP2015127299A (en) 2015-07-09
AR092351A1 (en) 2015-04-15
TW201408290A (en) 2014-03-01

Similar Documents

Publication Publication Date Title
EA201300200A1 (en) N - ((6-AMINOPIRIDIN-3-IL) METHYL) HETEROARILKARBOXAMIDES AS KALLYCREIN INHIBITORS IN PLASMA
RS54873B1 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CO6511251A2 (en) CHEMICAL COMPOUNDS
CY1123456T1 (en) METHOD OF PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROME-4-ONE DERIVATIVES AND THEIR USE IN THE PREPARATION OF PHARMACEUTICAL SUBSTANCES
ECSP12012208A (en) ORAL FORMULATIONS AND LIPOPHYLIC SALTS OF METHYLNTREXONE
CO6420351A2 (en) PESTICIDED COMPOSITIONS
CO6331463A2 (en) NEW DERIVATIVES OF TRIAZOLO (4,3-A) PIRIDINA, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NEW USE IN PARTICULARLY AS MET INHIBITORS
UY32126A (en) SOLID PHARMACEUTICAL COMPOSITION
CO6741154A2 (en) Triazolopyridine Compounds
UY34916A (en) "SOLID PREPARATION CONTAINING ACID [(3S) -6 -) {2´, 6´-DIMETIL-4´- [3- (METILSULFONIL) PROPOXI] BIFENIL-3-IL} METOXI) -2,3-DIHYDRO-1 -BENZOFURAN-3-IL] ACETIC "
CL2013003563A1 (en) Compounds derived from gambogic acid amides and their salts; pharmaceutical composition comprising them, useful in the treatment of glioblastoma.
NI201100149A (en) DERIVATIVES OF TIADIAZOLES AND OXADIAZOLES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY.
CR20140053A (en) DEOXICOLIC ACID FORMULATIONS AND SALTS OF THE SAME
NI201100051A (en) SALTS OF N - [6 - (CIS - 2,6 - DIMETHYL - MORPHOLIN - 4 - IL) - PYRIDIN - 3 - IL] - 2 - METHYL - 4 '- (TRIFLUORO - METOXI) - [1, 1' - BIPHENYL ] - 3 - CARBOXAMIDE.
AR089486A1 (en) PHARMACEUTICAL PREPARATION INCLUDING b-CYCLODEXTRINE REPLACED
ES2585558T3 (en) Use of 3-carboxy-N-ethyl-N, N-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
UY32333A (en) QUATERNARY DERIVATIVES OF PIRIDINE AND USE OF THE SAME
ES2513569T3 (en) Prolonged release formulation comprising a metastin derivative
TH129179A (en)
TH158502A (en) Heterocyclic compounds
TH156221A (en) 4- (8-methoxy-1 - ((1-methoxipropane-2-il) -2- (tetrahydro-2H-pyran-4-il) - 1H-imidaiso [4.5-C] -quinolin-7-il) -3,5-dimethyl isosazole And their use as a bromodomain inhibitor.
TH173507A (en) Welded-loop derivatives of dihydropyrimidoes as HBV inhibitors
TH105092A (en) Benzoquinasoline derivatives
TH168988A (en) Fibroblast growth factor receptor inhibitor
TH1701003364A (en) 3- (6-LcoxC-5-Chlorobenzo [D] isoxazole-3-Il) propanoic acid as useful as a monooxi kinurenene inhibitor. Genes

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20140715